Compare JF & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JF | KTTA |
|---|---|---|
| Founded | 2012 | 2020 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 15.6M |
| IPO Year | 2017 | 2021 |
| Metric | JF | KTTA |
|---|---|---|
| Price | $0.90 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.6K | ★ 1.4M |
| Earning Date | 12-01-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $486,559.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3130.37 |
| 52 Week Low | $0.81 | $0.32 |
| 52 Week High | $1.19 | $2.06 |
| Indicator | JF | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.09 | 49.53 |
| Support Level | $0.81 | $0.42 |
| Resistance Level | $1.03 | $0.57 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 0.13 | 48.59 |
J and Friends Holdings Ltd providing merchant digitalization and commerce-enablement solutions to small and medium enterprises (SME). Its solutions feature critical functionality that SMEs need to engage with consumers, manage their operations, accept payments, and grow their business. Such solutions empower single- and multi-location retailers, restaurants, and other SMEs to compete successfully in an omni-channel market environment by engaging with consumers across online, mobile, and physical channels. The group conducts all of its current operations in Australia and generates revenues from continuing operations are derived from within Australia.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.